news
![](https://gibf-bio.com/sites/default/files/custom-img/news/news-desktop.png)
![nectin-immunome](/sites/default/files/2024-08/nectin-immunome_0.jpg)
Nectin Therapeutics and Immunome Inc. have reached a collaboration on monoclonal antibodies
Nectin Therapeutics, Ltd., the parent company of Guangzhou Nectin Pharmaceutical Co., Ltd., a project invested by GIBF2 recently announced a global exclusive license agreement with Immunome Inc. for a monoclonal antibody molecule.
![投资组合向右箭头](/sites/default/files/2023-09/effect-ar-black.png)
![innovalve](/sites/default/files/2024-08/%E5%BE%AE%E4%BF%A1%E5%9B%BE%E7%89%87_20240805110236.jpg)
Congratulations! Prof. Shlomo Noy, a partner of GIBF, has co-founded the medical device company Innovalve, which has been acquired by the American medical device giant Edwards Lifesciences for $300 million
Recently, the American medical device giant Edwards Lifesciences announced the completion of the acquisition of Innovalve Bio Medical (hereinafter referred to as Innovalve), a spin-off from the Sheba Medical Center in Israel, for $300 million in cash. The acquisition plan is expected to be completed by the end of 2024, at which time Innovalve will be integrated into Edwards Lifesciences' Transcatheter Mitral and Tricuspid Valve Therapies (TMVT) 'product group, a news that has attracted widespread attention in the biomedical field.
![投资组合向右箭头](/sites/default/files/2023-09/effect-ar-black.png)
![nectin(for news)](/sites/default/files/2024-05/%E5%BE%AE%E4%BF%A1%E5%9B%BE%E7%89%87%E7%BC%96%E8%BE%91_20240509112016.jpg)
GIBF invests $10 Million in Nectin Therapeutics to Advance Novel Pipeline of First-in-Class Immunotherapies and Antibody Drug Conjugates
(6 May, 2024) Guangzhou-Israel Biotechnology Fund (GIBF) announced today that it has invested $10 million in Nectin Therapeutics Ltd, proceeds from financing to support ongoing clinical development of lead program targeting PVR as well as IND-enabling activities for multiple ADC candidates.
![投资组合向右箭头](/sites/default/files/2023-09/effect-ar-black.png)
![nectin EIC news](/sites/default/files/2024-03/EIC%20Accelerator%20Results%2011.2023.png)
Breaking news - Nectin winning the EIC funding
(18 March, 2024) Nectin Therapeutics Ltd. (" Nectin "), the parent company of Guangzhou Nectin Pharma Ltd. has been selected as one of the 42 recipients of EIC funding in the 2023 EIC Accelerator from a competitive field of 1,083 proposals and 242 companies that were reviewed.
![投资组合向右箭头](/sites/default/files/2023-09/effect-ar-black.png)
![shuki-外交特别贡献奖](/sites/default/files/2024-01/shuki-%E5%A4%96%E4%BA%A4%E7%89%B9%E5%88%AB%E8%B4%A1%E7%8C%AE%E5%A5%96.jpg)
Dr. Shuki Gleitman receives Certificates of Appreciation from Israeli Foreign Affairs
(25 Dec, 2023) Israeli Foreign Affairs Minister Mr. Eli Cohen awarded certificates of appreciation to businessmen and organizations for their contribution to Israel's foreign relations and strengthening its global position.
![投资组合向右箭头](/sites/default/files/2023-09/effect-ar-black.png)
![visionix news](/sites/default/files/2023-12/%E5%BE%AE%E4%BF%A1%E6%88%AA%E5%9B%BE_20231217144820.png)
New partnership between 20/20NOW and Visionix Americas
(16 Nov, 2023) Visionix USA is proud to share they recently entered a strategic alliance with 20/20NOW to help bring cost effective, in-office, quality synchronous tele-optometry comprehensive eye exams and ocular telemedicine closer to more patients throughout the United States.
![投资组合向右箭头](/sites/default/files/2023-09/effect-ar-black.png)
![silexion](/sites/default/files/2023-12/silexion.png)
Silexion Therapeutics Presented The LODER™ Phase 2 Summary Results In The 2023 ESMO Immuno-Oncology Congress
(30 Oct, 2023) Results from a multinational Phase 2 clinical study (Protact Trial) of siRNA directed against the oncogenic KRAS G12D and G12V mutations in an extended release formulation (Loder™) was presented at the 2023 European Society for Medical Oncology (ESMO) annual congress (Abstract 1626P).
![投资组合向右箭头](/sites/default/files/2023-09/effect-ar-black.png)
![角膜视力](/sites/default/files/2023-09/Corneat-logo%404x.jpg)
FDA Clears CorNeat EverPatch, World's First Non-Degradable Synthetic Tissue Substitute for Ophthalmic Surgery
(8 Jun, 2023) CorNeat Vision's EverPatch utilizes EverMatrix™, a novel material technology able to integrate with surrounding tissue
![投资组合向右箭头](/sites/default/files/2023-09/effect-ar-black.png)
![kamari news](/sites/default/files/2023-12/kamaryinvest.jpg)
Kamari Pharma Raises $8 Million from the Sino-Israeli GIBF2 Fund
(18 Sep, 2022) Kamari Pharma announced the completion of an $8 million investment by the Chinese fund GIBF2.
![投资组合向右箭头](/sites/default/files/2023-09/effect-ar-black.png)
![广州中以生物投资基金](/sites/default/files/2023-09/CNV2_l.jpg)
Guangzhou Sino-Israel Biotech Investment Fund Completed a $ 4 Million Investment in the Israeli Subsidiary of CorNeat Vision
(11 Sep, 2021) Guangzhou Sino-Israel Biotech Investment Fund (GIBF) recently completed a $ 4 million investment in the Israeli subsidiary of Kornit Vision, which was established in Guangzhou, China.
![投资组合向右箭头](/sites/default/files/2023-09/effect-ar-black.png)
![二组图片](/sites/default/files/2023-07/qianyue-scaled.jpg)
GIBF (China-Israel) Fund Raised 300 million Dollars on the Second Fund
(31 May 2021) The Guangzhou Sino-Israel Bio-industry Investment Fund, headed by Israel’s former chief scientist, has already closed $200 million for its second fund to finance clinical trials.
![投资组合向右箭头](/sites/default/files/2023-09/effect-ar-black.png)